AzTrials
AzTrials

Mechanical VentilationPVA-detectionNCT07624786

Patient-Ventilator Asynchrony: Occurence and Clinical Impact in Usual Care

An observational study of Mechanical Ventilation and Patient-Ventilator Asynchrony, run by Erasmus Medical Center at 3 sites in Netherlands.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this observational study is to unravel the occurence, impact and relations of Patient-Ventilator Aynchrony (PVA) in mechanically ventilated patients. The main questions it aims to answer are: How often does PVA occur? What are relations between clinical characteristics and PVA occurence? What are relations… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
PVA classification software
How many people
110 participants
Where
3 sitesNetherlands
Study dates
21 Jul 2026to Feb 2027
How long will I take part?
3 Months
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adult patients admitted to the ICU that receive invasive mechanical ventilation.

Who may be able to join

  • Age > 18 years old.
  • Recordings available of ventilator waveforms synchronized with the patient's electronic health record during invasive mechanical ventilation.
  • Duration of mechanical ventilation of at least 24 hours.

Who cannot join

  • (Previous) registered objection of patient and/or relatives to re-use clinical data for research purposes
  • No consent for re-use of data for research

Trial locations and contacts

3 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Annemijn Jonkman, PhD contact

+3110-7035142

a.jonkman@erasmusmc.nl

Netherlands3 sites, 3 recruiting
  • Catharina Ziekenhuis Eindhoven (CZE)

    Eindhoven, North Brabant, 5623EJ

    Ashley de Bie, PhD, +3140-2399500, ashley.d.bie@catharinaziekenhuis.nl

    Ashley de Bie, PhD

    Recruiting
  • Leiden University Medical Center (LUMC)

    Leiden, South Holland, 2333ZA

    Bram Schoe, PhD, a.schoe@lumc.nl

    Bram Schoe, PhD

    Not yet recruiting
  • Erasmus Medical Center (EMC)

    Rotterdam, South Holland, 3015GD

    Annemijn Jonkman, PhD, +3110-7035142, a.jonkman@erasmusmc.nl

    Annemijn Jonkman, PhD

    Recruiting

Other trials in Netherlands

About this study

Official title: Unraveling the Clinical Impact of Patient-Ventilator Asynchrony in Usual Care

The goal of this observational study is to unravel the occurence, impact and relations of Patient-Ventilator Aynchrony (PVA) in mechanically ventilated patients. The main questions it aims to answer are:

  • How often does PVA occur?
  • What are relations between clinical characteristics and PVA occurence?
  • What are relations between PVA occurence and patient outcomes?

All questions will be assessed using data collected during the whole course of mechanical ventilation. Mechanically ventilated patients' medical data will be re-used. PVAs will be automatically classified on ventilator waveform data, using validated Deep Breath software.

Read the detailed description

Many ventilated patients show excessive breathing efforts and abnormal, irregular breathing. This patient-ventilator asynchrony (PVA) is associated with serious discomfort, lung injury, sleep disruption and higher mortality. PVA exists in many forms and is reported in 10-90% of patients, but identifying and resolving it is challenging, even for expert clinicians. Hence, PVA prevalence and impact is likely highly underestimated, and the direct causal link with worse outcomes is inconclusive. PVAs should be better dettected, understood and resovled to optimize the individual patient's treatment.

In a previous study, the investigators validated an AI-based algorithm capable of reliable PVA detection (Deep Breath software). In this study, the investigators will apply this algorithm to the collected ventilator waveform data (offline processing), in order to reliably assess PVA occurrence, and its relation with clinical outcomes and patient characteristics in current clinical care. Data of minimally 110 patients collected over the whole course of mechanical ventilation will be assessed. Patients will be included in three ICUs to promote generalizability.

The primary outcome will be the asynchrony index (in total and per PVA type) over time. Secondary outcomes will include, but are not limited to: clinical characteristics (e.g. respiratory and hemodynamic parameters, sedation), (ICU) mortality, ventilator free days at day 28 and 90, duration of ventilation, weaning success and reintubation rate.

Being tested
PVA classification software
Keywords
asynchrony, Patient-ventilator asynchrony, dyssynchrony, Patient-ventilator interaction, mechanical ventilation, AI, algorithm, classification algorithm, ICU, Artificial intelligence
Medical subject headings
Patient-Ventilator Asynchrony

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PVA classification softwareOther

    Patients will receive standard care, without an intervention. Data will be captured as part of standard care and analyzed for PVAs retrospectively, using dedicated offline software.

Study groups in NCT07624786
Study groupRoleWhat they receive
Adult patients admitted to the ICU that receive invasive mechanical ventilationPatients need to be >18 years old, receive mechanical ventilation for at least 24 hours and have recordings available of ventilator waveforms, synchronized with the patient's electronic health record, during invasive mechanical ventilation.
Receives: Other: PVA classification software

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Asynchrony index over time (aggregated and per PVA type)

    Measure of how much asynchrony occurs and at what time. This measure will be calculated for all PVA types together, as well as per PVA type. The investigators calculate this over time, to see when asynchrony occurs, as well as in total, to get a global PVA prevalence measure (over the whole duration of ventilation).

    Measured: 28 days

Secondary outcomes (21)
  1. Use of sedatives (cumulative dose and type)

    Measured: 28 days

  2. Mechanical ventilation settings

    Measured: 28 days

  3. Respiratory parameters

    Measured: 28 days

  4. Hemodynamic parameters

    Measured: 28 days

  5. Relevant medication

    e.g. vasoactive agents, delirium related medication, analgesics

    Measured: 28 days

  6. Use of assist devices

    e.g. dialysis, pacemaker, ventricular assist device, ECMO

    Measured: 28 days

  7. Gas exchange parameters

    e.g. P/F ratio, PaO2, PaCO2, pH, bicarbonate

    Measured: 28 days

  8. Blood inflammatory biomarkers

    upon availability in the patient's electronic chart, e.g. CRP, lactate

    Measured: 28 days

  9. Sedation depth

    Richmond Agitation-Sedation Scale (RASS-score). This score ranges from -5 to +4, where a more positive score indicates more agitation.

    Measured: 28 days

  10. Reported delirium

    Reported delirium, observed via the Delirium Observation Screening (DOS), or the Intensive Care Delirium Screening Checklist (ICDSC), depending on the standard of care of the participating center. The DOS ranges from 0-13, with a score ≥3 indicating delirium. The ICDSC ranges from 0-8, with 0-3 indicating absence of delirium and a score of ≥4 inidicating delirium.

    Measured: 28 days

  11. Illness severity score (SOFA-score)

    SOFA-score. This score ranges from 0-24, with increasing scores reflecting more abnormal physiology and biochemistry or an increasing degree of intervention.

    Measured: 28 days

  12. ICU mortality

    Mortality during ICU stay

    Measured: 90 days

  13. Mortality at day 28

    Mortality at day 28

    Measured: 28 days

  14. Mortality at day 90

    Mortality at day 90

    Measured: 90 days

  15. Duration of ventilation

    Duration of ventilation in hours or days

    Measured: 28 days

  16. Ventilator free days (at day 28)

    Number of ventilator free days at day 28

    Measured: 28 days

  17. Ventilator free days (at day 90)

    Number of ventilator free days at day 90

    Measured: 90 days

  18. Reintubation rate

    Number of times reintubation occured, reported as % of patients needing reintubation.

    Measured: 28 days

  19. Weaning success

    Weaning success rate (%), defined as seven consecutive days without ventilator support

    Measured: 28 days

  20. ICU length of stay

    Length of ICU stay, measured in days

    Measured: 28 days

  21. Complications

    Complications (e.g. ventilator associated pneumonia and ICU acquired weakness) as reported in the patient file.

    Measured: 28 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Jun 2026
  2. Study start21 Jul 2026
  3. Primary completionNov 2026 (estimated)
  4. Study completionFeb 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Other
Enrolment
110 participants (estimated)
Target duration
3 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT07624786
Sponsor's protocol ID
MEC-2025-0353
Other IDs
EMCLSH24018
Acronym
PVA-detection
Status last verified
May 2026
First submitted
13 May 2026
Last updated
13 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: The final dataset will be available on reasonable request, with removed/anonymized timestamps for pseudonimization. The request will be reviewed by the PI, depending on the topic/quality of the proposal and including a plan for publication/authorship, and ensuring that the request meets legal and organizational requirements. Sharing of data for reuse by third parties will always only involve de-identified datasets and via a data transfer agreement.

Questions about this trial

What is this clinical trial studying?

An observational study of Mechanical Ventilation and Patient-Ventilator Asynchrony, run by Erasmus Medical Center at 3 sites in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 13 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Annemijn Jonkman, PhD (+3110-7035142, a.jonkman@erasmusmc.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Asynchrony index over time (aggregated and per PVA type) (time frame: 28 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in